

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No. **773**
RLL-238US

In Re Application Of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,049		Unassigned	26815	unknown	

Title: **DERIVATIVES OF 2,2,4-TRISUBSTITUTED TETRAHYDROFURAN AS ANTIFUNGAL AGENTS**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-238US

In Re Application: SALMAN et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/511,049		Unassigned	26815	unknown	

Title: DERIVATIVES OF 2,2,4-TRISUBSTITUTED TETRAHYDROFURAN AS ANTIFUNGAL AGENTS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by ^{EXPRESS} First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ^{EXPRESS} first-class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

July 8, 2005

(Date)

Michelle Morgan
Signature of Person Mailing Correspondence

Michelle Morgan

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

George E. Heibel
Signature

Dated: July 8, 2005

George E. Heibel, Esq.
Reg. No. 42,648

CUSTOMER NO. 26815

CC:

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-2004-01 US

Serial No.: 10/511,049

Applicants: SALMAN *et al.*

Filed: 10/12/2004

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,992,421	2/12/1991	De <i>et al.</i>	514	19	
	A2	5,039,676	8/13/1991	Saksena <i>et al.</i>	514	254	
	A3	5,371,101	12/6/1994	Itoh <i>et al.</i>	514	383	
	A4	5,486,625	1/23/1996	Leong <i>et al.</i>	549	448	
	A5	5,661,151	8/26/1997	Saksena <i>et al.</i>	514	252	
	A6	5,703,236	12/30/1997	Saksena <i>et al.</i>	544	366	
	A7	6,034,248	3/7/2000	Itoh <i>et al.</i>	548	253	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	WO 98/34934	8/13/1998	PCT	C07D	405/14		
	B2	EP 0 252 875	1/27/1993	EPO	A01N	46/653		
	B3	EP 0 296 518	12/28/1988	EPO	C07D	405/14		
	B4	EP 0 335 446	10/4/1989	EPO	C07D	405/06		
	B5	EP 0 443 980	8/28/1991	EPO	C07D	417/06		
	B6	EP 0 539 938	5/5/1993	EPO	C07D	405/06		
	B7	EP 0 555 186	8/11/1993	EPO	B27K	3/34		
	B8	JP 9-12574	1/14/1997	Japan	C07D	405/06		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Fromtling, "Overview of Medically Important Antifungal Azole Derivatives", <i>Clinical Microbiology Reviews</i> , 1(2):187-217 (1988)
C2	Greenspan, "Treatment of oropharyngeal candidiasis in HIV-positive patients", <i>The Journal of the American Academy of Dermatology</i> , 31:S51-S55 (1994)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Group: